NCT06097793View on ClinicalTrials.gov

KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

KSD-101

Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Kousai Bio Co., Ltd.

OTHER